According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

A court-appointed special master recommended a bid backed by Gold Reserve and Koch over a rival hedge-fund offer. Krispy Kreme's top finance executive, Jeremiah Ashukian, is leaving the doughnut maker ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Eli Lilly and Company (NYSE: LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

The Howard County Board of Education is suing several Big Pharma companies for allegedly inflating insulin prices, affecting ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

Celestica is a strong company, with a remarkable and fortunate market position, but the valuation is now too high for strong ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...